WIA
CMMB

Wetzel Investment Advisors’s Chemomab Therapeutics CMMB Stock Holding History

Wetzel Investment Advisors’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,750
Closed -$12K – 128
2025
Q1 		$12K Buy
2,750
+250
+10% +$1.75K 0.01% 122
2024
Q4 		$18.1K Buy
+2,500
New +$15.8K 0.01% 121

Other funds holding CMMB

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
YLHM
Yelin Lapidot Holdings Management Tel Aviv, Israel $480M AUM 42.17% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wetzel Investment Advisors's CMMB Position: Q2 2025 in Review

Wetzel Investment Advisors sold out of Chemomab Therapeutics (CMMB) in Q2 2025, closing a stake of 2,750 shares — an estimated $12K sold.

Wetzel Investment Advisors first reported a position in CMMB in Q4 2024 and held it in 2 quarters. The position peaked at $18.1K in Q4 2024. 14 funds tracked by Wall St. Rank hold CMMB as of Q2 2025.

  • Wetzel Investment Advisors reported no remaining Chemomab Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Wetzel Investment Advisors sold 2,750 Chemomab Therapeutics shares in Q2 2025, an estimated $12K.
  • Wetzel Investment Advisors first reported a position in Chemomab Therapeutics in Q4 2024 and held it in 2 quarters.
  • Wetzel Investment Advisors's Chemomab Therapeutics position peaked at $18.1K in Q4 2024.
  • 14 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2025.

Based on Wetzel Investment Advisors's 13F filing for Q2 2025, filed 18 Jul 2025.